Literature DB >> 8398804

Experimental murine chronic hepatitis: results following intrahepatic inoculation of human uveitis mycoplasma-like organisms.

L A Johnson1, E Wirostko, B M Wirostko.   

Abstract

Mycoplasma-like organisms (MLO) are non-cultivated intracellular cell-wall deficient pathogenic bacteria with a distinctive ultrastructural appearance. Diagnosis of MLO disease depends on finding the organisms in parasitized cells using a transmission electron microscope. MLO are a well studied cause of transmissible chronic plant disease responsive to antibiotics. MLO have recently been found to cause human chronic uveitis, orbital, and retinal disease with autoimmune features. Ophthalmic leucocytes in these patients display MLO parasitization. Inoculation of human uveitis MLO into mouse eyelids produced chronic uveitis. MLO also disseminated to produce randomly distributed lethal systemic disease including chronic hepatitis. MLO parasitized leucocytes were present in all disease sites. Direct intrahepatic inoculation of human hepatic pathogens is a simple and efficient technique to produce murine hepatitis. This report describes the delayed onset widespread inflammatory liver disease produced by direct intrahepatic inoculation of human chronic uveitis MLO in 12 of 20 mice versus 0 in 40 controls (P < 0.05). The liver disease was accompanied by elevated serum SGOT levels, splenomegaly, and accelerated mortality. All 12 inflamed livers displayed MLO parasitized leucocytes versus 0 of 10 control livers. The resemblance of human chronic active hepatitis, massive hepatic necrosis, and post-necrotic cirrhosis to the MLO induced murine liver disease, the role of molecular biologic techniques in the detection and classification of those bacteria, and in therapy of MLO disease are discussed.

Entities:  

Mesh:

Year:  1993        PMID: 8398804      PMCID: PMC2001851     

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  18 in total

1.  The uses and limitations of intraocular biopsy.

Authors:  W S Foulds
Journal:  Eye (Lond)       Date:  1992       Impact factor: 3.775

2.  Chronic intracellular leucocytoclastic bacterial vitritis. A transmission electron microscopic study of the monocytes.

Authors:  E Wirostko; L Johnson; W Wirostko
Journal:  J Submicrosc Cytol Pathol       Date:  1988-04

3.  Chronic idiopathic vitritis. Ultrastructural properties of bacteria-like bodies within vitreous leukocyte phagolysosomes.

Authors:  L A Johnson; E Wirostko
Journal:  Am J Clin Pathol       Date:  1986-07       Impact factor: 2.493

4.  Induction of chronic lethal Australia antigen hepatitis in mice.

Authors:  L A Johnson; E Wirostko
Journal:  Am J Pathol       Date:  1976-01       Impact factor: 4.307

5.  Mouse lethal cardiovascular disease: induction by human leucocyte intracellular Mollicutes.

Authors:  L Johnson; E Wirostko; W Wirostko
Journal:  Br J Exp Pathol       Date:  1988-04

6.  Chronic idiopathic vitritis. Cytopathogenicity of unusual bacteria for vitreous polymorphonuclear leukocytes.

Authors:  L Johnson; E Wirostko; B Wirostko
Journal:  J Submicrosc Cytol       Date:  1987-01

7.  Mouse exophthalmic chronic orbital inflammatory disease. Induction by human leucocyte intracellular Mollicutes.

Authors:  E Wirostko; L Johnson; W Wirostko
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1988

8.  Mouse interstitial lung disease and pleuritis induction by human Mollicute-like organisms.

Authors:  E Wirostko; L A Johnson; W J Wirostko
Journal:  Br J Exp Pathol       Date:  1988-12

9.  Chronic leucocytoclastic bacterial vitritis. A lymphocyte transmission electron microscopic study.

Authors:  E Wirostko; L Johnson; W Wirostko
Journal:  J Submicrosc Cytol       Date:  1987-10

10.  Transmission of chronic idiopathic vitritis in mice by inoculation of human vitreous containing leucocyte phagolysosomal bacteria-like bodies.

Authors:  E Wirostko; L A Johnson; B M Wirostko
Journal:  Lancet       Date:  1986-08-30       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.